Leading manufacturer and supplier of dental infection control products, Quadralene, has been 100% acquired by Getinge, a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences.
The deal, which has been negotiated over the last 7 months by Breeze Corporate Finance and Shakespeare Martineau Lawyers, safeguards all the jobs at Dentisan’s manufacturing base in Derby and will see the creation of a Centre of Excellence for chemistry and instrument disinfection at the company’s headquarters in the city.
Getinge was founded in Sweden in 1904 and today employs over 10,000 people worldwide, running 20 production sites in 8 different countries. Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. Their offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science and it operates in more than 135 countries.
“With the acquisition of Quadralene we will bring additional value and support to our customers in their mission to reduce hospital acquired infections” says Stéphane Le Roy, President Surgical Workflows at Getinge. “Quadralene has a great reputation in the field of decontamination, and we are excited that they join Getinge as the future cornerstone of our newly created Centre of Excellence, dedicated to chemistry and instrument disinfection.”
Bob Newsome, Managing Director of Quadralene believes the acquisition is in the best interests of the Quadralene team and its customers, “We have a long partnership with Getinge that up until now has been our largest customer. In supporting Getinge to realize its strategic ambition, Quadralene is rightly being recognized for its expertise in decontamination technology. Our aim is to continue to innovate within our market, which has been the hallmark of our growth to date, and by becoming an in-house consumables manufacturer we hope to expand the global appeal of the whole Getinge portfolio.”
For more information visit:
This article was written by Medilink Member, Quadralene
